PegBio Co Ltd

PegBio Co., Ltd. is a biopharmaceutical company based in Hangzhou, China, focused on research and development of medicines for chronic diseases. Its pipeline includes PB-119, a GLP-1 receptor agonist for type 2 diabetes and obesity; PB-718, a long-acting GLP-1 receptor agonist that has completed Phase Ib/IIa trials for non-alcoholic steatohepatitis (NASH) and is also being developed for obesity; and PB-1902, an opioid receptor antagonist in Phase II trials for opioid-induced constipation and obesity. The company is also developing GLP-1 for first-line treatment of type 2 diabetes and obesity, and PB-722, which has received FDA orphan drug designation for congenital hyperinsulinemia. Additionally, it is conducting preclinical studies on PB-2301, a GLP-1/GIP dual agonist, and PB-2309, a GLP-1/GIP/glucagon triple receptor agonist, for type 2 diabetes, NASH, and obesity. PegBio has a research and development collaboration with Rani Therapeutics to expand its obesity pipeline across multiple novel candidates. The company was incorporated in 2008.

Biotech & Genomic Medicine▲

Rani Therapeutics and PegBio Ink R&D Deal for Obesity and Metabolic Disease Candidates

Rani Therapeutics and PegBio have entered a research and development collaboration to evaluate multiple candidates from PegBio's obesity and metabolic disease pipeline using Rani's proprietary RaniPill platform. The companies will work together on pre-clinical development of RaniPill formulations for selected molecules, with plans to advance suitable candidates into clinical development. RaniPill is a swallowable robotic capsule designed to deliver biologics orally with injectable-like bioavailability. The agreement is expected to expand Rani's obesity portfolio beyond its existing programs, potentially adding multiple candidates with differentiated mechanisms of action.

2565.HK ▲RANI ▲

Biotech & Genomic Medicine

RTTNews·70dRead more →